New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
11:59 EDTCELGCelgene weakness an overreactions, says Wells Fargo
Wells Fargo said Celgene weakness related to the upcoming Markman hearing and the UK's The National Institute for Health and Care Excellence guidance that thalidomide vs. Revlimid should be considered in most second line MM patients is an overreaction. The firm said the Markman hearing has been an overhang but there are many steps needed before a final outcome and that the UK's decision is not meaningful given current reimbursement is only for 3rd+ line anyway. The firm would use weakness in Celgene as a buying opportunity and reiterates its Outperform rating.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 23, 2015
07:21 EDTCELGCelgene receives positive CHMP opinion for ABRAXANE
Subscribe for More Information
January 21, 2015
08:36 EDTCELGCelgene price target raised to $139 from $115 at RW Baird
Baird raised its price target on Celgene to $139 from $115 following last week's guidance from the company. Baird reiterated its Outperform rating on Celgene shares.
January 16, 2015
09:11 EDTCELGCelgene says oral Otezla approved by European Commission in 2 indications
Celgene International, a wholly-owned subsidiary of Celgene Corporation, announced that the European Commission has granted marketing authorisation for OTEZLA, the company’s oral selective inhibitor of phosphodiesterase 4, in two therapeutic indications: For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light. Alone or in combination with Disease Modifying Antirheumatic Drugs, for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy. The marketing authorization is based on efficacy and safety data from two Phase III programs, ESTEEM AND PALACE, which demonstrate a maintained clinical response among patients with psoriasis and psoriatic arthritis treated with OTEZLA through 52 weeks, across multiple endpoints. The EC decision follows the positive opinion issued by the Committee for Medicinal Products for Human Use in November 2014.12 OTEZLA will be launched in the European Union in the coming months in accordance with local requirements.
January 15, 2015
07:59 EDTCELGAmerican Society of Clinical Oncology to hold a symposium
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use